AU602210B2 - Creation of Inventions and Patents with Artificial Intelligence

AU602210B2 – Novel beta-d-phenyl-thioxylosides, their method of preparation and their use as therapeutics
– Google Patents

AU602210B2 – Novel beta-d-phenyl-thioxylosides, their method of preparation and their use as therapeutics
– Google Patents
Novel beta-d-phenyl-thioxylosides, their method of preparation and their use as therapeutics

Download PDF
Info

Publication number
AU602210B2

AU602210B2
AU15219/88A
AU1521988A
AU602210B2
AU 602210 B2
AU602210 B2
AU 602210B2
AU 15219/88 A
AU15219/88 A
AU 15219/88A
AU 1521988 A
AU1521988 A
AU 1521988A
AU 602210 B2
AU602210 B2
AU 602210B2
Authority
AU
Australia
Prior art keywords
group
formula
preparation
mol
atom
Prior art date
1987-05-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU15219/88A
Other versions

AU1521988A
(en

Inventor
Francois Bellamy
Jean Millet
Soth Samreth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Fournier Industrie et Sante SAS

Original Assignee
Fournier Innovation et Synergie SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1987-05-04
Filing date
1988-04-27
Publication date
1990-10-04

1988-04-27
Application filed by Fournier Innovation et Synergie SA
filed
Critical
Fournier Innovation et Synergie SA

1988-11-10
Publication of AU1521988A
publication
Critical
patent/AU1521988A/en

1990-10-04
Application granted
granted
Critical

1990-10-04
Publication of AU602210B2
publication
Critical
patent/AU602210B2/en

1991-11-28
Assigned to FOURNIER INDUSTRIE ET SANTE
reassignment
FOURNIER INDUSTRIE ET SANTE
Request to Amend Deed and Register
Assignors: FOURNIER INNOVATION ET SYNERGIE

2008-04-27
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

238000000034
method
Methods

0.000
title
claims
description
28

239000003814
drug
Substances

0.000
title
claims
description
4

238000002360
preparation method
Methods

0.000
title
description
47

125000002252
acyl group
Chemical group

0.000
claims
abstract
description
7

125000005843
halogen group
Chemical group

0.000
claims
abstract
description
6

125000004093
cyano group
Chemical group

*C#N

0.000
claims
abstract
description
5

229910052717
sulfur
Inorganic materials

0.000
claims
abstract
description
5

125000000449
nitro group
Chemical group

[O-][N+](*)=O

0.000
claims
abstract
description
3

125000004430
oxygen atom
Chemical group

0.000
claims
abstract
description
3

125000004434
sulfur atom
Chemical group

0.000
claims
abstract
description
3

238000002560
therapeutic procedure
Methods

0.000
claims
abstract
description
3

125000004435
hydrogen atom
Chemical group

[H]*

0.000
claims
abstract
4

OKKJLVBELUTLKV-UHFFFAOYSA-N
Methanol
Chemical compound

OC
OKKJLVBELUTLKV-UHFFFAOYSA-N
0.000
claims
description
57

239000000203
mixture
Substances

0.000
claims
description
24

150000001875
compounds
Chemical class

0.000
claims
description
23

230000008018
melting
Effects

0.000
claims
description
18

238000002844
melting
Methods

0.000
claims
description
18

-1
4-(4–Cyanobenzoyl)phenyl
Chemical group

0.000
claims
description
11

239000012429
reaction media
Substances

0.000
claims
description
8

239000012442
inert solvent
Substances

0.000
claims
description
7

239000002253
acid
Substances

0.000
claims
description
6

238000006243
chemical reaction
Methods

0.000
claims
description
6

LFQSCWFLJHTTHZ-UHFFFAOYSA-N
Ethanol
Chemical compound

CCO
LFQSCWFLJHTTHZ-UHFFFAOYSA-N
0.000
claims
description
5

DGAQECJNVWCQMB-PUAWFVPOSA-M
Ilexoside XXIX
Chemical compound

C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+]
DGAQECJNVWCQMB-PUAWFVPOSA-M
0.000
claims
description
4

125000004432
carbon atom
Chemical group

0.000
claims
description
4

125000001309
chloro group
Chemical group

Cl*

0.000
claims
description
4

150000002500
ions
Chemical class

0.000
claims
description
4

229910052751
metal
Inorganic materials

0.000
claims
description
4

239000002184
metal
Substances

0.000
claims
description
4

239000012074
organic phase
Substances

0.000
claims
description
4

239000011734
sodium
Substances

0.000
claims
description
4

229910052708
sodium
Inorganic materials

0.000
claims
description
4

WKBOTKDWSSQWDR-UHFFFAOYSA-N
Bromine atom
Chemical group

[Br]
WKBOTKDWSSQWDR-UHFFFAOYSA-N
0.000
claims
description
3

239000002841
Lewis acid
Substances

0.000
claims
description
3

ISWSIDIOOBJBQZ-UHFFFAOYSA-N
Phenol
Chemical compound

OC1=CC=CC=C1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N
0.000
claims
description
3

229910052801
chlorine
Inorganic materials

0.000
claims
description
3

150000007517
lewis acids
Chemical class

0.000
claims
description
3

238000011282
treatment
Methods

0.000
claims
description
3

ZAMOUSCENKQFHK-UHFFFAOYSA-N
Chlorine atom
Chemical compound

[Cl]
ZAMOUSCENKQFHK-UHFFFAOYSA-N
0.000
claims
description
2

229910052794
bromium
Inorganic materials

0.000
claims
description
2

239000000460
chlorine
Substances

0.000
claims
description
2

229940079593
drug
Drugs

0.000
claims
description
2

238000010438
heat treatment
Methods

0.000
claims
description
2

238000010992
reflux
Methods

0.000
claims
description
2

230000001225
therapeutic effect
Effects

0.000
claims
description
2

FYYHWMGAXLPEAU-UHFFFAOYSA-N
Magnesium
Chemical compound

[Mg]
FYYHWMGAXLPEAU-UHFFFAOYSA-N
0.000
claims
1

125000002777
acetyl group
Chemical group

[H]C([H])([H])C(*)=O

0.000
claims
1

125000001931
aliphatic group
Chemical group

0.000
claims
1

101150007166
ensa gene
Proteins

0.000
claims
1

239000011777
magnesium
Substances

0.000
claims
1

229910052749
magnesium
Inorganic materials

0.000
claims
1

239000000546
pharmaceutical excipient
Substances

0.000
claims
1

NQLVQOSNDJXLKG-UHFFFAOYSA-N
prosulfocarb
Chemical compound

CCCN(CCC)C(=O)SCC1=CC=CC=C1
NQLVQOSNDJXLKG-UHFFFAOYSA-N
0.000
claims
1

230000008707
rearrangement
Effects

0.000
claims
1

239000000126
substance
Substances

0.000
claims
1

230000002785
anti-thrombosis
Effects

0.000
abstract
description
8

229960004676
antithrombotic agent
Drugs

0.000
abstract
description
4

239000000047
product
Substances

0.000
description
31

XEKOWRVHYACXOJ-UHFFFAOYSA-N
Ethyl acetate
Chemical compound

CCOC(C)=O
XEKOWRVHYACXOJ-UHFFFAOYSA-N
0.000
description
21

239000000243
solution
Substances

0.000
description
11

YMWUJEATGCHHMB-UHFFFAOYSA-N
Dichloromethane
Chemical compound

ClCCl
YMWUJEATGCHHMB-UHFFFAOYSA-N
0.000
description
9

XLYOFNOQVPJJNP-UHFFFAOYSA-N
water
Substances

O
XLYOFNOQVPJJNP-UHFFFAOYSA-N
0.000
description
9

VEXZGXHMUGYJMC-UHFFFAOYSA-M
Chloride anion
Chemical compound

[Cl-]
VEXZGXHMUGYJMC-UHFFFAOYSA-M
0.000
description
8

CSNNHWWHGAXBCP-UHFFFAOYSA-L
Magnesium sulfate
Chemical compound

[Mg+2].[O-][S+2]([O-])([O-])[O-]
CSNNHWWHGAXBCP-UHFFFAOYSA-L
0.000
description
8

WQDUMFSSJAZKTM-UHFFFAOYSA-N
Sodium methoxide
Chemical compound

[Na+].[O-]C
WQDUMFSSJAZKTM-UHFFFAOYSA-N
0.000
description
8

239000002904
solvent
Substances

0.000
description
8

238000003756
stirring
Methods

0.000
description
7

YXFVVABEGXRONW-UHFFFAOYSA-N
Toluene
Chemical compound

CC1=CC=CC=C1
YXFVVABEGXRONW-UHFFFAOYSA-N
0.000
description
6

239000003480
eluent
Substances

0.000
description
6

238000001704
evaporation
Methods

0.000
description
6

230000008020
evaporation
Effects

0.000
description
6

238000001914
filtration
Methods

0.000
description
6

230000007935
neutral effect
Effects

0.000
description
6

239000012299
nitrogen atmosphere
Substances

0.000
description
6

125000001997
phenyl group
Chemical group

[H]C1=C([H])C([H])=C(*)C([H])=C1[H]

0.000
description
6

238000005406
washing
Methods

0.000
description
6

VYPSYNLAJGMNEJ-UHFFFAOYSA-N
Silicium dioxide
Chemical compound

O=[Si]=O
VYPSYNLAJGMNEJ-UHFFFAOYSA-N
0.000
description
5

229920001429
chelating resin
Polymers

0.000
description
5

239000012279
sodium borohydride
Substances

0.000
description
5

229910000033
sodium borohydride
Inorganic materials

0.000
description
5

QTBSBXVTEAMEQO-UHFFFAOYSA-M
Acetate
Chemical compound

CC([O-])=O
QTBSBXVTEAMEQO-UHFFFAOYSA-M
0.000
description
4

239000013078
crystal
Substances

0.000
description
4

239000000706
filtrate
Substances

0.000
description
4

239000006260
foam
Substances

0.000
description
4

229910052943
magnesium sulfate
Inorganic materials

0.000
description
4

235000019341
magnesium sulphate
Nutrition

0.000
description
4

239000011541
reaction mixture
Substances

0.000
description
4

229920005989
resin
Polymers

0.000
description
4

239000011347
resin
Substances

0.000
description
4

239000007858
starting material
Substances

0.000
description
4

UHOVQNZJYSORNB-UHFFFAOYSA-N
Benzene
Chemical compound

C1=CC=CC=C1
UHOVQNZJYSORNB-UHFFFAOYSA-N
0.000
description
3

IAZDPXIOMUYVGZ-UHFFFAOYSA-N
Dimethylsulphoxide
Chemical compound

CS(C)=O
IAZDPXIOMUYVGZ-UHFFFAOYSA-N
0.000
description
3

KFZMGEQAYNKOFK-UHFFFAOYSA-N
Isopropanol
Chemical compound

CC(C)O
KFZMGEQAYNKOFK-UHFFFAOYSA-N
0.000
description
3

ZMXDDKWLCZADIW-UHFFFAOYSA-N
N,N-Dimethylformamide
Chemical compound

CN(C)C=O
ZMXDDKWLCZADIW-UHFFFAOYSA-N
0.000
description
3

208000007536
Thrombosis
Diseases

0.000
description
3

239000003638
chemical reducing agent
Substances

0.000
description
3

229940073584
methylene chloride
Drugs

0.000
description
3

VLKZOEOYAKHREP-UHFFFAOYSA-N
n-Hexane
Chemical compound

CCCCCC
VLKZOEOYAKHREP-UHFFFAOYSA-N
0.000
description
3

125000000636
p-nitrophenyl group
Chemical group

[H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O

0.000
description
3

239000000725
suspension
Substances

0.000
description
3

OFQCQIGMURIECL-UHFFFAOYSA-N
2-[2-(diethylamino)ethyl]-2′,6′-dimethylspiro[isoquinoline-4,4′-oxane]-1,3-dione;phosphoric acid
Chemical compound

OP(O)(O)=O.O=C1N(CCN(CC)CC)C(=O)C2=CC=CC=C2C21CC(C)OC(C)C2
OFQCQIGMURIECL-UHFFFAOYSA-N
0.000
description
2

RTKMFQOHBDVEBC-UHFFFAOYSA-N
3-bromo-3-buten-1-ol
Chemical compound

OCCC(Br)=C
RTKMFQOHBDVEBC-UHFFFAOYSA-N
0.000
description
2

PZASAAIJIFDWSB-CKPDSHCKSA-N
8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid
Chemical compound

FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1
PZASAAIJIFDWSB-CKPDSHCKSA-N
0.000
description
2

IJGRMHOSHXDMSA-UHFFFAOYSA-N
Atomic nitrogen
Chemical compound

N#N
IJGRMHOSHXDMSA-UHFFFAOYSA-N
0.000
description
2

HEDRZPFGACZZDS-UHFFFAOYSA-N
Chloroform
Chemical compound

ClC(Cl)Cl
HEDRZPFGACZZDS-UHFFFAOYSA-N
0.000
description
2

RTZKZFJDLAIYFH-UHFFFAOYSA-N
Diethyl ether
Chemical compound

CCOCC
RTZKZFJDLAIYFH-UHFFFAOYSA-N
0.000
description
2

VEXZGXHMUGYJMC-UHFFFAOYSA-N
Hydrochloric acid
Chemical compound

Cl
VEXZGXHMUGYJMC-UHFFFAOYSA-N
0.000
description
2

102220472148
Protein ENL_E11N_mutation
Human genes

0.000
description
2

JUJWROOIHBZHMG-UHFFFAOYSA-N
Pyridine
Chemical compound

C1=CC=NC=C1
JUJWROOIHBZHMG-UHFFFAOYSA-N
0.000
description
2

UIIMBOGNXHQVGW-UHFFFAOYSA-M
Sodium bicarbonate
Chemical compound

[Na+].OC([O-])=O
UIIMBOGNXHQVGW-UHFFFAOYSA-M
0.000
description
2

FAPWRFPIFSIZLT-UHFFFAOYSA-M
Sodium chloride
Chemical compound

[Na+].[Cl-]
FAPWRFPIFSIZLT-UHFFFAOYSA-M
0.000
description
2

101150052863
THY1 gene
Proteins

0.000
description
2

DTQVDTLACAAQTR-UHFFFAOYSA-N
Trifluoroacetic acid
Chemical compound

OC(=O)C(F)(F)F
DTQVDTLACAAQTR-UHFFFAOYSA-N
0.000
description
2

WGLPBDUCMAPZCE-UHFFFAOYSA-N
Trioxochromium
Chemical compound

O=[Cr](=O)=O
WGLPBDUCMAPZCE-UHFFFAOYSA-N
0.000
description
2

125000004429
atom
Chemical group

0.000
description
2

SRBFZHDQGSBBOR-UHFFFAOYSA-N
beta-D-Pyranose-Lyxose
Natural products

OC1COC(O)C(O)C1O
SRBFZHDQGSBBOR-UHFFFAOYSA-N
0.000
description
2

239000011651
chromium
Substances

0.000
description
2

229910000423
chromium oxide
Inorganic materials

0.000
description
2

230000008034
disappearance
Effects

0.000
description
2

238000003818
flash chromatography
Methods

0.000
description
2

229940075610
mercuric cyanide
Drugs

0.000
description
2

229910052987
metal hydride
Inorganic materials

0.000
description
2

150000004681
metal hydrides
Chemical class

0.000
description
2

238000007254
oxidation reaction
Methods

0.000
description
2

239000012071
phase
Substances

0.000
description
2

239000002244
precipitate
Substances

0.000
description
2

RYVMUASDIZQXAA-UHFFFAOYSA-N
pyranoside
Natural products

O1C2(OCC(C)C(OC3C(C(O)C(O)C(CO)O3)O)C2)C(C)C(C2(CCC3C4(C)CC5O)C)C1CC2C3CC=C4CC5OC(C(C1O)O)OC(CO)C1OC(C1OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OCC(O)C(O)C1O
RYVMUASDIZQXAA-UHFFFAOYSA-N
0.000
description
2

239000013557
residual solvent
Substances

0.000
description
2

VSEMHWJZHMSSPC-UHFFFAOYSA-N
s-[4-(3-cyanobenzoyl)phenyl] n,n-dimethylcarbamothioate
Chemical compound

C1=CC(SC(=O)N(C)C)=CC=C1C(=O)C1=CC=CC(C#N)=C1
VSEMHWJZHMSSPC-UHFFFAOYSA-N
0.000
description
2

239000000377
silicon dioxide
Substances

0.000
description
2

150000003573
thiols
Chemical class

0.000
description
2

JFALSRSLKYAFGM-UHFFFAOYSA-N
uranium(0)
Chemical compound

[U]
JFALSRSLKYAFGM-UHFFFAOYSA-N
0.000
description
2

DDHAJDHHPYXNKH-UHFFFAOYSA-N
(3-nitrophenyl)-(4-sulfanylphenyl)methanone
Chemical compound

[O-][N+](=O)C1=CC=CC(C(=O)C=2C=CC(S)=CC=2)=C1
DDHAJDHHPYXNKH-UHFFFAOYSA-N
0.000
description
1

RYHBNJHYFVUHQT-UHFFFAOYSA-N
1,4-Dioxane
Chemical compound

C1COCCO1
RYHBNJHYFVUHQT-UHFFFAOYSA-N
0.000
description
1

OHVLMTFVQDZYHP-UHFFFAOYSA-N
1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone
Chemical compound

N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O
OHVLMTFVQDZYHP-UHFFFAOYSA-N
0.000
description
1

SCVJRXQHFJXZFZ-KVQBGUIXSA-N
2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione
Chemical compound

C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1
SCVJRXQHFJXZFZ-KVQBGUIXSA-N
0.000
description
1

PUAQLLVFLMYYJJ-UHFFFAOYSA-N
2-aminopropiophenone
Chemical compound

CC(N)C(=O)C1=CC=CC=C1
PUAQLLVFLMYYJJ-UHFFFAOYSA-N
0.000
description
1

RVBPKXNAHYSUGP-UHFFFAOYSA-N
3-(4-hydroxybenzoyl)benzonitrile
Chemical compound

C1=CC(O)=CC=C1C(=O)C1=CC=CC(C#N)=C1
RVBPKXNAHYSUGP-UHFFFAOYSA-N
0.000
description
1

UAYAHZSTUJLJMY-UHFFFAOYSA-N
3-(4-sulfanylbenzoyl)benzonitrile
Chemical compound

C1=CC(S)=CC=C1C(=O)C1=CC=CC(C#N)=C1
UAYAHZSTUJLJMY-UHFFFAOYSA-N
0.000
description
1

ZETIVVHRRQLWFW-UHFFFAOYSA-N
3-nitrobenzaldehyde
Chemical compound

[O-][N+](=O)C1=CC=CC(C=O)=C1
ZETIVVHRRQLWFW-UHFFFAOYSA-N
0.000
description
1

MBBQVULVJVBHCH-UHFFFAOYSA-N
4-(4-sulfanylbenzoyl)benzonitrile
Chemical compound

C1=CC(S)=CC=C1C(=O)C1=CC=C(C#N)C=C1
MBBQVULVJVBHCH-UHFFFAOYSA-N
0.000
description
1

LFZQCJLFQTXGKW-UHFFFAOYSA-N
4-[(4-nitrophenyl)methyl]phenol
Chemical compound

C1=CC(O)=CC=C1CC1=CC=C([N+]([O-])=O)C=C1
LFZQCJLFQTXGKW-UHFFFAOYSA-N
0.000
description
1

125000004801
4-cyanophenyl group
Chemical group

[H]C1=C([H])C(C#N)=C([H])C([H])=C1*

0.000
description
1

125000004203
4-hydroxyphenyl group
Chemical group

[H]OC1=C([H])C([H])=C(*)C([H])=C1[H]

0.000
description
1

241000331231
Amorphocerini gen. n. 1 DAD-2008
Species

0.000
description
1

XUKUURHRXDUEBC-KAYWLYCHSA-N
Atorvastatin
Chemical compound

C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1
XUKUURHRXDUEBC-KAYWLYCHSA-N
0.000
description
1

BVKZGUZCCUSVTD-UHFFFAOYSA-M
Bicarbonate
Chemical compound

OC([O-])=O
BVKZGUZCCUSVTD-UHFFFAOYSA-M
0.000
description
1

101100087530
Caenorhabditis elegans rom-1 gene
Proteins

0.000
description
1

241001559589
Cullen
Species

0.000
description
1

MYMOFIZGZYHOMD-UHFFFAOYSA-N
Dioxygen
Chemical compound

O=O
MYMOFIZGZYHOMD-UHFFFAOYSA-N
0.000
description
1

108010074860
Factor Xa
Proteins

0.000
description
1

PXGOKWXKJXAPGV-UHFFFAOYSA-N
Fluorine
Chemical compound

FF
PXGOKWXKJXAPGV-UHFFFAOYSA-N
0.000
description
1

UFHFLCQGNIYNRP-UHFFFAOYSA-N
Hydrogen
Chemical compound

[H][H]
UFHFLCQGNIYNRP-UHFFFAOYSA-N
0.000
description
1

206010020608
Hypercoagulation
Diseases

0.000
description
1

238000006994
Koenigs-Knorr glycosidation reaction
Methods

0.000
description
1

241000234435
Lilium
Species

0.000
description
1

241001465754
Metazoa
Species

0.000
description
1

101100087528
Mus musculus Rhoj gene
Proteins

0.000
description
1

101100305983
Mus musculus Rom1 gene
Proteins

0.000
description
1

229920002565
Polyethylene Glycol 400
Polymers

0.000
description
1

ZLMJMSJWJFRBEC-UHFFFAOYSA-N
Potassium
Chemical compound

[K]
ZLMJMSJWJFRBEC-UHFFFAOYSA-N
0.000
description
1

241000700157
Rattus norvegicus
Species

0.000
description
1

241000283984
Rodentia
Species

0.000
description
1

101100294399
Schizosaccharomyces pombe (strain 972 / ATCC 24843) not1 gene
Proteins

0.000
description
1

101100027997
Schizosaccharomyces pombe (strain 972 / ATCC 24843) omh1 gene
Proteins

0.000
description
1

BQCADISMDOOEFD-UHFFFAOYSA-N
Silver
Chemical compound

[Ag]
BQCADISMDOOEFD-UHFFFAOYSA-N
0.000
description
1

UIIMBOGNXHQVGW-DEQYMQKBSA-M
Sodium bicarbonate-14C
Chemical compound

[Na+].O[14C]([O-])=O
UIIMBOGNXHQVGW-DEQYMQKBSA-M
0.000
description
1

NINIDFKCEFEMDL-UHFFFAOYSA-N
Sulfur
Chemical compound

[S]
NINIDFKCEFEMDL-UHFFFAOYSA-N
0.000
description
1

WFWLQNSHRPWKFK-UHFFFAOYSA-N
Tegafur
Chemical compound

O=C1NC(=O)C(F)=CN1C1OCCC1
WFWLQNSHRPWKFK-UHFFFAOYSA-N
0.000
description
1

ATJFFYVFTNAWJD-UHFFFAOYSA-N
Tin
Chemical compound

[Sn]
ATJFFYVFTNAWJD-UHFFFAOYSA-N
0.000
description
1

206010047249
Venous thrombosis
Diseases

0.000
description
1

125000000218
acetic acid group
Chemical group

C(C)(=O)*

0.000
description
1

150000001298
alcohols
Chemical class

0.000
description
1

229940127218
antiplatelet drug
Drugs

0.000
description
1

239000003699
antiulcer agent
Substances

0.000
description
1

239000003849
aromatic solvent
Substances

0.000
description
1

125000003118
aryl group
Chemical group

0.000
description
1

239000012298
atmosphere
Substances

0.000
description
1

GDTBXPJZTBHREO-UHFFFAOYSA-N
bromine
Substances

BrBr
GDTBXPJZTBHREO-UHFFFAOYSA-N
0.000
description
1

150000001720
carbohydrates
Chemical class

0.000
description
1

235000014633
carbohydrates
Nutrition

0.000
description
1

230000002490
cerebral effect
Effects

0.000
description
1

238000004587
chromatography analysis
Methods

0.000
description
1

230000000052
comparative effect
Effects

0.000
description
1

108010057108
condensin complexes
Proteins

0.000
description
1

238000005947
deacylation reaction
Methods

0.000
description
1

238000010908
decantation
Methods

0.000
description
1

ZXSBDSGRQIWJPM-UHFFFAOYSA-N
dimethylcarbamothioic s-acid
Chemical compound

CN(C)C(S)=O
ZXSBDSGRQIWJPM-UHFFFAOYSA-N
0.000
description
1

230000006806
disease prevention
Effects

0.000
description
1

208000037265
diseases, disorders, signs and symptoms
Diseases

0.000
description
1

239000012154
double-distilled water
Substances

0.000
description
1

238000001035
drying
Methods

0.000
description
1

FCZCIXQGZOUIDN-UHFFFAOYSA-N
ethyl 2-diethoxyphosphinothioyloxyacetate
Chemical compound

CCOC(=O)COP(=S)(OCC)OCC
FCZCIXQGZOUIDN-UHFFFAOYSA-N
0.000
description
1

125000001495
ethyl group
Chemical group

[H]C([H])([H])C([H])([H])*

0.000
description
1

229910052731
fluorine
Inorganic materials

0.000
description
1

239000011737
fluorine
Substances

0.000
description
1

238000005858
glycosidation reaction
Methods

0.000
description
1

229910052736
halogen
Inorganic materials

0.000
description
1

150000002367
halogens
Chemical class

0.000
description
1

230000023597
hemostasis
Effects

0.000
description
1

229910052739
hydrogen
Inorganic materials

0.000
description
1

239000001257
hydrogen
Substances

0.000
description
1

XLYOFNOQVPJJNP-UHFFFAOYSA-M
hydroxide
Chemical compound

[OH-]
XLYOFNOQVPJJNP-UHFFFAOYSA-M
0.000
description
1

125000002887
hydroxy group
Chemical group

[H]O*

0.000
description
1

125000004029
hydroxymethyl group
Chemical group

[H]OC([H])([H])*

0.000
description
1

230000000055
hyoplipidemic effect
Effects

0.000
description
1

230000003027
hypercoagulation
Effects

0.000
description
1

230000000871
hypocholesterolemic effect
Effects

0.000
description
1

229910052740
iodine
Inorganic materials

0.000
description
1

WSFSSNUMVMOOMR-BJUDXGSMSA-N
methanone
Chemical compound

O=[11CH2]
WSFSSNUMVMOOMR-BJUDXGSMSA-N
0.000
description
1

239000002808
molecular sieve
Substances

0.000
description
1

PHWISQNXPLXQRU-UHFFFAOYSA-N
n,n-dimethylcarbamothioyl chloride
Chemical compound

CN(C)C(Cl)=S
PHWISQNXPLXQRU-UHFFFAOYSA-N
0.000
description
1

229910052757
nitrogen
Inorganic materials

0.000
description
1

LYGJENNIWJXYER-UHFFFAOYSA-N
nitromethane
Chemical compound

C[N+]([O-])=O
LYGJENNIWJXYER-UHFFFAOYSA-N
0.000
description
1

239000012454
non-polar solvent
Substances

0.000
description
1

230000003287
optical effect
Effects

0.000
description
1

230000003647
oxidation
Effects

0.000
description
1

229910052760
oxygen
Inorganic materials

0.000
description
1

239000001301
oxygen
Substances

0.000
description
1

230000020477
pH reduction
Effects

0.000
description
1

239000008188
pellet
Substances

0.000
description
1

230000000144
pharmacologic effect
Effects

0.000
description
1

239000000106
platelet aggregation inhibitor
Substances

0.000
description
1

239000002798
polar solvent
Substances

0.000
description
1

239000011591
potassium
Substances

0.000
description
1

229910052700
potassium
Inorganic materials

0.000
description
1

UMJSCPRVCHMLSP-UHFFFAOYSA-N
pyridine
Natural products

COC1=CC=CN=C1
UMJSCPRVCHMLSP-UHFFFAOYSA-N
0.000
description
1

230000036647
reaction
Effects

0.000
description
1

PZFXOQGRHCKSHK-UHFFFAOYSA-N
s-[4-(4-cyanobenzoyl)phenyl] n,n-dimethylcarbamothioate
Chemical compound

C1=CC(SC(=O)N(C)C)=CC=C1C(=O)C1=CC=C(C#N)C=C1
PZFXOQGRHCKSHK-UHFFFAOYSA-N
0.000
description
1

229920006395
saturated elastomer
Polymers

0.000
description
1

239000012047
saturated solution
Substances

0.000
description
1

238000000926
separation method
Methods

0.000
description
1

210000002966
serum
Anatomy

0.000
description
1

229910052709
silver
Inorganic materials

0.000
description
1

239000004332
silver
Substances

0.000
description
1

URGAHOPLAPQHLN-UHFFFAOYSA-N
sodium aluminosilicate
Chemical compound

[Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O
URGAHOPLAPQHLN-UHFFFAOYSA-N
0.000
description
1

235000017557
sodium bicarbonate
Nutrition

0.000
description
1

229910000030
sodium bicarbonate
Inorganic materials

0.000
description
1

239000011780
sodium chloride
Substances

0.000
description
1

125000004646
sulfenyl group
Chemical group

S(*)*

0.000
description
1

239000011593
sulfur
Substances

0.000
description
1

238000004809
thin layer chromatography
Methods

0.000
description
1

VLPFTAMPNXLGLX-UHFFFAOYSA-N
trioctanoin
Chemical compound

CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC
VLPFTAMPNXLGLX-UHFFFAOYSA-N
0.000
description
1

201000002282
venous insufficiency
Diseases

0.000
description
1

238000005303
weighing
Methods

0.000
description
1

Classifications

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS

C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals

C07H15/20—Carbocyclic rings

C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems

A—HUMAN NECESSITIES

A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE

A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

A61P7/00—Drugs for disorders of the blood or the extracellular fluid

A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

C—CHEMISTRY; METALLURGY

C07—ORGANIC CHEMISTRY

C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS

C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups

Abstract

The present invention relates, by way of novel industrial products, to osides selected from the group consisting of: (i) the beta -D-phenylthioxylosides of the formula: in which: R represents a hydrogen atom, a halogen atom, a nitro group or a cyano group, A represents the sulfur atom or the oxygen atom, B represents a CH2, CHOH or CO group and Y represents the hydrogen atom or an acyl group; and (ii) epimers thereof when B is CHOH. These products are useful in therapy as antithrombotics.

Description

FIFTY DO-jA-‘ NETDOLL SIXTY DOLLAR 4 ?l~his docu me t C nan h rnlendniJents md ne ecIo 9 and is correct f(2,
-I-
C0111ONWEALTH OF AUSTRALIA The Patents Act 1952-1969 Name of Aplicant: Address of Applicant: Actual Inventors: FOURNIER INNOVATION ET SYNAERGIE 38 AVENUE HOCHE, 75008 PARIS,
FPANCE
S0TH SA14RETH FRANCOIS BELLAMY JEAN MILLE~T 0 a C 4 0 C 0 0 0 a a e C 0 a00 0000CC 0 Address for Service: GR. CULLEN COMPANY, Patent Trade Mark Attorneys, Dalgety House, 79 Eagle Street, BRISBANE, QLD. 4000
AUSTRALIA
COMPLETE SPECIFICATION FOR THE INVENTION ENTITLED: “NOVEL $-D-PHENYL-THIQXYLOSIDE$, THEIR METHOD OF PREPARATION AND THEIR USE AS THERAPEUTICS” The following statement is a full description of the invention incl.uding ‘the best method of perform~ing it known to us: -41 L A Inventor or.
ventors. 4. The basic application referred to in paragraph 2 of this Declaration was the first application made in a Convention country in respect of the invention the subject of the application.
DECLARED ARIS… D E C L A R E D at 1 i day of.Ap.ri 1 Signature. (7.
Manager To: FOURNIER INNOVATION ET SYNERGIE :THE COMMISSIONER OF PATENTS. The present invention relates, by way of novel industrial products, to the -D-phenylthioxyloside derivatives of the formula I below. It also relates to therapy as antithrombotics, especially venous antithrombotics.
European Patent Document B-0051023 has already proposed benzoylphenyloside and c-_hydroxybenzylphenyloside derivatives as antiulcer agents, platelet aggregation inhibitors, anihrobotics and cerebral oxygenators.
European Patent Document A-0133103 also discloses benzylphenylosides which are useful as hypocholesterolemics and hypolipidemics, some of these compounds, in particular the product of Example 1, having antithrombotic effects as well.
It has now been found that the -D-phenylthioxyloside derivatives according to the invention, which are structurally different from the known products of the prior art, are useful in the treatment and prevention of diseases associated with circulatory disorders, especially as venous antithrombotics.
Unexpectedly, the derivatives according to the 25 invention have antithrombotic properties which are greatly superior to those of the known products of the prior art, cf. the res’ its of the comparative tests collated in Table III below.
The novel products according to the invention are selected from the group consisting of: the -D-phenylthioxylosides of the formula: yo O Y
OY
:I l /J i
IL>)
P
-2 i L J c in which: RreprLUenS,(_1 8 hydr-oge-n atoni, I halogen t’ anir grou.) or a cyano group, A represents the sulfur ator or the! oxygen(!1 c:onl, B rep resents a CF 2′ C1101I or CO group and Y represents the hydrogen citor or an ary 1 gtroup; an d (ii) epimers thereof when 13 is COCH The hyd roxylI groupi of the P3-D-thioxy lo-no residue are capable of being acylated especi ally acetylated The present invention therefore includes the derivatives of the formula I in which the hydroxyl groups Of the P-D-thioxylose residue are acyla~ed, especially acetylated.
The fluorine, chlorine and bromine atomsa way be mentioned among the halogen atoms included in the definition of the group R, the preferred halogen atom being the chlorine atom.
Among the acyl groups which are suitable according to the invention, there may be mentioned those wrhich contain a total of 2 to 5 carbon atoms, the preferred 4cyl group being CH 3
CO.
The compounds of the formula I and the corresponding acylated Compounds can be prepatred according to a glycosidation reaction wherein: 25 i) a compound of the formula: HA-as-o (11) in which A, B and R are defined as above, is reacted with a thioxylose derivative selected from the group consisting of the halogenoacyithioxylosides and a~ylthioxylosides of the formulae: Y YQo Ha Iy V 11 f V I IIb) in which Hal represents a hal2on aLv’., wwih as C1 or Br (the bromine atom buing MWe prefuerrcA IaIO ,,rn atoei here) anid Y rep resents on acy I group enpecia lily afn ailipha tic acyl group contai inng a total of to 5 carbon atoms and preferably the acety I group, in an inert solvent, at a rate of i ol of It to about 1.1 to 1.2 mol of thioxylose derivative, in th~e preoernce of an acid acceptor or a Lewis acid, one.
(ii) if necessary, a deacyla tion reaction is carrEd out at a temperature between room teaipvrature (15-25C) and the refiux temperature Of the renction medium, An a C-Clower alcohol (preferably methanol), in the presence of a metal. alcoholate (preferably mngnesiun methylathior method, it is important in stage (i) that the compouind VINl is in the conf ipuration. On the other hand, the compound VIMi can be in the cor configuration or a miXture of both configurations.
The acylated or non-acyla ted compounds of the formula I in which 13 represents either CHM or CH 2 can also be obtained by reduction, according tn a method known per se, of the compounds of the formula I (acylated or non-acylated) in which 13 represents CO or CHOU.
Again, the acylated or non-acylated compounds of the formula in which 13 represents CO can be obtained by oxidation, according to a method known. per se, of the compounds of the formula I (acylated or, non-acylated) in which, B represents CH 2 or CHOH The following are recommended among the -4glycosidation method,,, known to those skilled in the art: -the KOENIGS-KNORR method (described in “The Carbohydrates, Chemistry anid Biochemistry”, 2nd Edi tion New York and London: Academic Press (1972), vo Ilume I A, page:3 29 5-301 ),wh ich 111Vo Ives, cond ensin g 1 phenol ur n thiophuncfl of Lhe! tormula II1 with a haloenocy~lc~yioideVila, in an inert solvent selected from polar aind apolar a;ol-yen ts (for exampl e dimethylformamide tet!rahydrof)uran i, dioxane acetc,ml trile iitromellthane 1)(11:1011, tOlUene xf-lones and J tixturen, thereof), in thu preosunco of a. proton accept::r Such LIS mercur-ic Cyn1ide Or S1Ule trfiflate (sJilvur trifluoronethiyls.ulfona t an11d -Llth HELFERICH1- metlhod (Ibid em, pager, 292-294), 15 whiLch involves condensing an acylthloxyloside VITIb with a phenol or a Lhiophenol. of the formula IT, in an inert solvent selected from aromatic solvents, chlorinated solventLs, eLthers anid mixtures thervot i n the presence off a Lewis acid.
In a preferredI method of carrying out the invention, if A represents a Sulfur atom in the compound of the formula II, itL Is recommended in StaU of the method to condense 1 mol. of the thiol II with about 1. .1 to 1.2 mol of halogenoacyithioxyloside VIlla in an inert solvent selected from polar and apolar solvents, in the presence of mercuric cyainide It will.b advantageous t s in a 1/1 (v:v) benzene/nitromethane mixture, in the presence of 1.1 to 1.3 mol of mercuric cyanide, at a temperature between 0 0 C and the reflux temperature of the reaction medium, preferably at about 40-50 0 C, for 1 to 4 hours, preferably for about 2 hours.
In another preferred method of carrying out the invention, if A represents an oxygen atom and B represents L 11~ r hyIci r q p: hoP omtpon”11 t U’ 1 I I i t r rvuommuniid 1 i n i s t A t ho t m tho z to widc se 1 t u r f thp ph n i eu eiet fji r 5 oetAs v-a 1 1o, jia ud v’:t ace tyl I A -omo-rI-D-5-t h i oxy 1opyr ino szidein niryo o f I.I t o 1. 3 ma I aof s i I v a r r r i I a L 1 L o n ~“eatmeoni. W7: d Lanorder”; of ho venous” Circulation, Futrther chiaracl.eristlcs! aid idVantajges of tieL iiv et in will be understw I-ood mo1re7 a’lua-rly from the f ol Lowingl’ description of preparativo examples whic’I In no waye imply a limitat ion but aro given by way of” Illustration, ind of resul1to of” pharmacological test.
The angles of. optical rotations [0z-1 2 are expresseod in 2 5 Alegrees iind were measuredl at 290’r PRE~PARATION T Preparation of 0-4-(4-iitrobenzoyl)phenyLt dimethylthioca rbama te 1.4 g (0.025 niol) of potassium, hydroxide pellets 3 0 are added to a suspension of 5.,4 g (0.0224 aol) of 4hydroxyphenyl 4-nitrophenyl meathanione in 60 nil of water, The reaction miXture is heated at 50 0 C for two hOUrs, with. vigorouis stirring. The mixture is then cooled to 0 0 G anid a SOIlution of 3.5 g (0.029 aol) of~ diimethylthio.C4 ca rhbanoyb Irh Ior ide in 15 Ql LtLctihydrvuri (THIl)K Od ded ciro pw ise. Whon t ho add1ition I, c’ ump t t h r(‘8cL ion riLxttiru 5 Li nrrt’d for 13 :Miiiito nt MY 0 lio’n for one hour K 20 C. Th” r”AC:I On u8 Wiil in hi !Iy rol IY :’uu In 25 )f I Ni, t 4011 at C, [PI t 1 r o ai ii1′ 1, I tort W V in wo h d A t vito 11 4 IT of lie %nish inie Q, nonL ram Wa r d r i iq’ t r i c r t, ta I L ed f -on t V h yl1 nu o hI1 r i d u/hp =me “1 A:t u v at 168 “M Z E11A R ATI0 IN 11 4′ 0 Pr L. 1) ar aL o a o F 5~ A-no i -1 r n a~m t c h he t ud I t. 2 00 -!10’C hr 4 ur 11,1(1dor ,i “I r Z attiojuliro ;ith Mi. re by 1110 C*i ,dtCC )ft hi’2 vtalrtinel ritrial iLi nonitaro 1 biy th ia Kqvu Mori o 0*~v/v the r TICI” QmI e~o* S it quanti K- yieltl-uxpLcLCd pruduct; “Min in 198-109C. t PRMPARATI0Oi T11T Ot~ropa raitioni o f 4-rierc apuhrv 1)->ut1 I Vt ro p 11e I v 1n(‘1 rlhan~ g (0.030 not) of the proauct oht Iinud, i P r eI)art iou n [I are d11tiolvocl in 90 ml of dlioxane, undi yr o ni troge-n Anosphorv,’ 0#039 mat- of siodium mothyloto ~87 Ltolticuu a motlhaitlo I) is~ added and tho dinaO~lpflt’ifl a f the starting material isi mniOtored by thn Layer ch roma tography unin g a hoxane/e thy 1 acetate mixtu re (0;1 v/v) as the eluent After stirring (Air one hour ait room tomperature, the reac tion mixture Is. hydrolyac’ by acidification with q I R solution of hydrochior-t acid at OWC The expectedl product is a~ttnCted with ethyl acetate, The organic ph~ase o-htannd is was~hed wiLth water until the PH of the washings Lo, Rcutr~l. dried over magnesium sulfate and filterud aind the so Evvnt is r~1pr tdof- to give 7 .3 g (yield; 93%) of the J otxpccted product nltingp Ot. 116-117’C.
1P, E11A R ATI 0N I V P ra pa rn tionr of (4-nti; ro be nz yl 1) phenyl1 -2 ,3 4-triccty I- 1, 5- d i Io- D-vopranoas;i d e A ml.-ture of iSO0 ml of zinhydrouos ie nz en e 13 0 ril of nitronethane and 30 g of a 0.4 tin molecular alevo (marko tri by the coripany P1 ME~RCK) is stirred at Tk~i’oo temipera tare for 15 minutes and 14,2 1,::(0,0553 mol) cC miercuric cyonide (Jg(CN) are then added A ft er the rul t i nixtuLre has been stirred for 10 minutes z~ room tomperoiturr, 19,6 .g (0,0552 not) of 2, 3,4-triare added, followedl by 13 g (0.050 riol of 4-riercaptophenyl 4at trophetyl ticmthanone in snall portions, When the dditi-, inComplete, the reaction mixture is heated at 40-50’C far four’ hours andl theon ftiltered on Celite diaqtoPU1CQoU.1 Oitica -f or filtration), The residue is washed several Linea with othyl acetate. The organlc phase obtained 1,s washed successively with a saturatod Solution Of 00odiur chloride, a 1 11 solution Of N,-01On(I an aSolution Of sodium chloride, and then with Vwater until the pit of the washings iS neu tral. It is dJriod over magnesium sulfate and f iltered and the oolvetit lo evaporated of f The yellowish oil obtained isa dissolved in 50 ml of ether and left at 4 0 C for 12 hours. The product crystllies A’e ilrton, 17.2 g of the expected product in the f configuration are obtaiined. The mother liquors are then evaporated and the procduats which they contaiin are soparated by flash r-hromatography using, a toluerie/othyl acetate miXture (8:1 v/v) as thec eluerit, This cinellty gives 18,6 g of the isomer (yield: 70O1) melting at 166t69 0 c 20 +92; C 0.5 (Cit and 5-9 g of the ./2 ~1 12 ~isomer (yie Lc 15%) in the form of a foam [o] 1 286; C 0.5 (CICK)).
PDREARATION V’ P r epa raLi o n o f (4 -4 ni t r ob1an zo 1)I p h e ny 1 1 5-d ithio0- -D-x y Io pY r anos 1. doe kX’1inp 1, I 18 g (0.0’337 [not.) ofL the pr od uctL o b ta in ed i n P r ep)ara t ion [iV ExamipLe la aire dIissol ved in a mixture of 100 mt of ethy I acetate and 300 nil of methanol under a nitrogen atmnosphere and 8,5 ml of an .olution of sodium miethytate in methanol are then added. After stirring fur two hours at room temperatre, the prec ipi tate formed is ff1ltered off and washed twice with nil of mthanol. The fitrate obtained is neutralized with Amberlite IR 120 resin to pli 4-5 and then, after filtration the solvent is evaporated off and the resulting evaporation residue is combined with the precipitate obtained previously. This gives 13.8 g (q ua ntitatv yileldi) of the expected product mliga 1831C [04 +60; C 0 ,5 DMS0) Prepa ra tio n o f (4-nitrophienyl )hydroxymethyI )_phenvl)- L Example 3 425 1 .2 g (OX0315 mol) of sodium borohydride are added in small portions, under a nitrogen atmosphere, to a suspension of 11.2 g (0.0275 mol) of the productI 4jobtained in Pre para tio n V (ERxam pl1e 1) The solution becomes hc.mogeneous af ter stirring for two hours at 0 0 C The reaction medium is neutralized with Amberlite R IR 120 regin (1-1 to pH- 4-5 and the solvent is evaporated off after filtration, The -resulting evaporation residue is purified on. a silica column using ethyl acetate as the elUent. This gives 11.2 g (quantitative 3 5 yield) of the expectead product Melting at 80 0 C
D
t 11..
13 C 0. ,(methnnol)).
PREPARATION VII Preparation of 4-niLro p len vl hydroxyme thyl LLhenvl 2, 3 4-tri-O-acetyl-i, 5-th~o-3-D-.,vyol~yrinoside Example 3a 4 *1 ii w 7 F, (0.0131 mol) of (4-(4-nitrobenzoyl )phenyl 2, 3, 4-tiri -O-ace ty 1-I 5-cl i th io- lopyranoside, obtained in Preparation IV (E7,xam,,ple 1a) arc- dissolved in 70 ml of mie tlano 1Lunder a ni trogen atmosphere and 0. 5 g (0.0131 molI) of sodium borohyd ride i~f- then added to the reactLion mixture at room temperature. The reaction medium is stirred f or 30 m-inutes and then acidif ied by the addition of AmbrliteR IR 120 resin to pHl 4-5. After filtration, the filtrate which has been collected is evapora ted to give 6.3 g (yield.
of the expected product in thle form of a yellow foam [o]20 C =0 .15 (methanol) PREPARATION VIII Preparation of (4-(4-nitrobenzyl phenyl 3 ,4-ty-i-Oacetyl-I 5-dithio-P-xviopy ranoside 3.3 g, (0.00616 aiol) of (4-((4-nitrophenyl)hydroxymethiyl )phenyl)-2,3,4-tri-0-aicetyl- xylopyranoside (Example 3a) obtained In Preparation VII are suspended in 17 ml of methyloe chloride, under a 25 nitrogen atmosphere. The reaction meodium is cooled to 0 0 C, 17 ml of trifluoroacetic acid are then added all at once and 470 mg (0.0123 mel) of sodium borohydride are added in small portion.-. The medium is stirred at 000 for 1.5 h. The reaction medium is hydrolyzed on ice and extracted with met!hylene chloride. The organic: phase obtained is washed with a saturated solution of bicarbonate and then with water until the p11 of tho washings is neutral,. Trhe organic phase is dried, filtered and then evaporated to give 2.77 S (yield: 87%) of the expected product in the form or a foam.
I I 4 .4 144 PREPARATION IX Preparation off itro ben zy I)ph eny I)-I 5-d it hio- Dxytopyranoside Example 4 2. 79 g (0.00537 mol) of itrobenzyl)phenvl)- 2 3,4-tr i-O–acety 1-1 5-d i th i I py ranosLd e obtained i n Prepa ratioan VIIfI are suspended i n 40 mlI of methanol and then 0.15 ml of- an 8T. soiution of sodium methylate in methanol is added at room temperature, with stirring, After stirring for 12 houris at room V temperature, the sodium methylate is neutralized with aR Amberlite I R 12 0 re s in H ).The reaction medium i s filtered the f ilItrate is evaporated and the resulting eva poratLion res id ue i s t hen pu r if ied b y f lash c hromatography using a methyl ene chloride/methanol mixture (95:5 v/v) aL. the eluent. This gives 1.3 g (yield; C re p ra ti n f4 .4 -n it rob en zy I )ph e nyQ-2, 1, 4 tr i-0arcet (0.01965 mol) of 4-(4-nitrobenzyl )phenol, 3 m of2,,6-trimethylpyridine, 70 ml of a, toluene/ n it rome thartie m i XtLUrO v1 v) a nd 10 S o f a 0 .4 nm molecular sieve are mixed SuICCeSSively at 3*C Under a nitrogen atmosphere. The reaction medium is stirred vigorouIsly for 20 minutes, 5.8 g (0.0225 not1) of silver tri~la to are then introdcedIC and 8.7 g (0.0245 mol of 1-bromio-2,3, 4-tri-0-icetyl-5-tho–D-xytnI~pyranoside nre added in 2.17 g portionis evory 30 minutes. vhe miXture iS Otired at 3’C for 20 11LM S inthe absnc of Light. The react ion c tmI t1rrdn e t anid the poocipitn tc washed three t imres With 200 Ml 33 off othyl Icetato. The fEl I rato obtained I w’lshec With S- 4 YA B (I)
OY
V 4 4 15 1 N HC1 and then with water until the pH of the washings is neutral. After drying over magnesium sulfate, filtra tion and evaporation, the yellowish oil obtained is purified by flash chromatography using a hexane/ ethyl acetate mixture as the eluent. This gives 3 g (yield: 30%) of the isomer melting at 134 0 C C 0.5 (CHC13)) and 3 g of the isomer ([d]D +284; C 0.4 (CHC1 3 PREPARATION XI Preparation of (4-(4-nitrobenzyl)phenyl)-5 thio–Dis nexylopyranoside Example 2 fil 2.5 g (0.005 mol) of the product obtained in Preparation X (Example 2a) are suspended in 150 ml of o 15 methanol at 0 0 C under a nitrogen atmosphere and 0.5 ml of an 8% solution of sodium methylate in methanol is R hours and Amberlite IR 120 resin (H is then added.
ol’ When neutral pH has been reached, the methanol is o 20 evaporated off under reduced pressure and the resulting evaporation residue is lyophilized to give 1.9 g S(quantitative yield) of the expected product melting at 166 0 C -21; C 0.5 (methanol)).
PREPARATION XII Preparation of (4-(4-nitrobenzoyl)phenyl)-2,3, 4 -tri-0acet yl-5-t hio–D-xyl opyranoside Example 1.1 g (0.0028 mol) of the product obtained in Preparation X (Example 2a), 50 ml of anhydrous methylene chloride, 0.66 g (0.043 ntol) of chromium oxide (Cr 0 3 and 12 ml of pyridine are mixed successively under a nitrogen atmosphere. The resulting mixture is oeated at 60 0 C for 24 hours, 0.66 g of chromium oxide :is then added and heating is continued for 24 hours. The organic phase is separated from the insoluble residue by organric lisise?. is Se :pa r:atd. ffni ehQi ins:O:uXe restde by the group consisting of the halogenoacylthioxylosides and acylthioxylosides of the formulae: L. 1 1 16 decantation. The insoluble residue is taken up with a solution of sodium bicarbonate and isopropyl alcohol and then extracted three times with methylene chloride.
The organic phases are combined, washed with a solution of sodium bicarbonate, with water until the pH of the washings is neutral, with 1 N hydrochloric acid and then with water until the pH of the washings is neutral, dried over magnesium sulfate and filtered and the filtrate is evaporated. The resulting crude evaporation residue is purified by flash chromatograph. using a chloroform/ethyl acetate mixture (1:1 v/v) as the i eluent. This gives 0.720 g of the starting material and 0.260 g (yield: 24%) of the expected product melting at 152 0 C ([cD -47; C 0.3 (CHCL 3 PREPARATION XIII Preparation of (4-((4-nitrophenyl)hydroxymethyl)p henyl)- -D-xylopyranoside Example 3 5.33 g (0.01 mol) of the product obtained in Preparation IV (Example la) are dissolved in 50 ml of anhydrous methanol under a nitrogen atmosphere and ml of an 8% solution of sodium methylate in methanol is then added. The mixture is stirred for I hour, the disappearance of the starting material being monitored by thin layer chromatography. When the starting material has totally disappeared, 0.4 mg (0.0105 mol) j of sodium borohydride (NaBH 4 is added in small portions and the disappearance of the previously formed acetylated intermediate is monitored. Finally, Amberlite R R 120 resin (H is added to the resulting mixture in order to neutralize the medium. After filtration, the filtrate is evaporated to dryness. The evaporation residue, which is obtained in the form of a foam, is taken up with double-distilled water and then lyophilized to give 4 g (quantitative yield) of the expected product melting -17- 20 at 8000 C 0.5 (methanol)).
D
PREPARATION XIV Preparation of (4-nitrophenyl)hydroxymethvl )2phenvl -D-x ylo pyra noside it 5 Example 8 Following the procedure described in Preparation XIII and starting from (4t-(4-nitrobenizoyl)plhenyl)-2,3,4- Preparation XII, the expected product melting at 108- 118’C is obtained with a quantitative yielsL C =0.5 (methanol)).
0 Prparaionof 4-mercaptophenyl 3-nitrophenyl methanone 001 15 1 and starting from 18 g (0.07407 aol) of 4hdoy phernyl 3-nitrophenyl methanone and 12.3 g (0.0992 aol) of dimethylthiiocarbamoyl chloride, 20.5 g (yield: 84%) of 0-4-(3-nitrobenzoyl )phenyl dime thyl thiocarbamate are obtained.
200 Following the procedure described in Preparation II and starting from 20.5 g (0.062 aol) of 0-4-(3- 0; nitrobenzoyl)phenyl dimethylthiocarbamate, 20.5 g (0.062 aol) (quantitative yield) of S-4-(3-nitrobenzoyl)phenyl dirnethylthiocarbamate are obtained.
Following the procedure described in Prepar-ation III and starting from 20.5 g (0.062 aol) of S-4-(3nitrobenzoyl)pheny1 dimethylthiocarbamate, 15.6 S (yield: 96%) of 4-inercaptophenyl 3-nitrophonyl methanone melting at 11400 are obtained.
PREPARATION XVI Preparation of 4-cyariophenyl 4-morcaptophll methnnone Following the procedure described in Preparatio~n I and starting from 5 8 (0.0224 aol) of 4-hydroxypheoiivl 3-nitropheny2. nethanone and 3.6 g (Q.0312 mol) of 33 clime thyi thl oci rbamoyl chloride, 5.6 g (yield: 76%) for about 2 hours.
In another preferred method of carrying out the invention, if A represents an oxygeni atom and B represents TN
V
4 18 O.-4-(4-cyanobenzoyl )phenyl dimethyithiocarbamate meltiny at 162’C are obtained.
Follow.ing the procedure described in Preparation 11 and starting from 5.2 g (0.0167 mol) of cyanobenzoyl)phenyl dimethyithiocarbamate, 5.2 g (quantitative yield) of S-4-(4-cyanobenzoyl )phenyl dimethylthiorarbaimate melting at 174’C are obtained.
Following the procedure described in Preparation III and starting from 18.6 g (0.059 mol) of S-4-(4cyanobenzoyl)phenyl dimethyLthiocarbamate,,12.5 g (yield: of 4-mercaptophenyl 4-cyanophenyl methanone melting at 156’C are obtained.
PREPARATION XVII Preparation of (4-(4-cyainohenzoyl)phenyl)-2, 3,4-tri-0acetvl-l 5-dithio-1 3 -1-xylopyraniioside Example 12a Following the procedure described in Preparation IV and starting from 6 q (0.0251 viol) of 4-nercaptophenyl 4-cyanophenyl muthanone ObtaLned in Preparation XVI, 9.8 q (0.0276 mol) of 2,3,4-tri-0-acetyl-1-bronmoand 7. 1 g (0.0276 inol) of mercuric cyanide, 7.3 g (yield: of the Pisoner me:lting at 172*C are obtailned 5 0; C
D
(Cudl 3 PREPARATION XVIII Preparation of 4(cynbnofpevl-.-ito yr ano sido Example 12 Vollowing the proced-ure described In Proparatien V and starting from 2 q (0.0356 mol) of thyi produc~t obtaiLned in Preparation XVII (Example 12a) and 0.75 taQl of an 8Z solution of sodium methylatc, 1.38 g (quantitative y:Lolc) of the expoctodc product mneiting aL 164’C arc obtaineOd (11 20 C 0. 197 (CH :0I1)”” to those skilled in the art, tor example by f rac tional crystalli-ation or chroma togra,)phy especially f lash chromatography i.e. chromatogriaphy on a silica column -19- PREPARATION XIX Preparation of (4-((4-cvanoplhenyl)hvdroxymethyl)phienyI~ 1, 5-dithio- -D-xylopyranioside- Example 13 Following the procedure described in Preparation VI and starting from 3.7 g (0.0095 mol) of the product obtained in Preparation XVIII (Example 12) and 0.370g (0.0097 mol) of sodium borohydride, 3 g (yield: 8 1%) ‘Iiof the expected product melting at 70-85’C are obtained 110 ([o6]D C =0.598 (CH 3 0H),- PREPARATION XX Separation of the two epimers of (4-nitrophenyl hydroxvmethyl )phenyl 1) Preparation of (+)-(4-((4-nitropienyl)hydroxy- 15methyl)phenyl)-1,5-dithio-p-D-xylopyranoside Example 16 11 .2 g of the mixture of epinerm 8 C =0,5 (methanol)) obtained in Preparation VI are recrystallized from 80 ml of ethyl acetate saturated with 90 wa ter. This gives 7.85 g of crystals +4; C -0.4 (methanol)) and a filtrate (F 1 The crystals are recrystallized from 150 ml of ethyl acetate containing 1% of water. Thio gives 3.15 g of 252 (ma thanol)) The crystalu (C 3 are III turn recrystallized from 16 ml of ethyl acetate saturate d with water. TIh in gives 1.43 g of crystals of the isomer melting at 141 0 C 20 (ehnl) 11C([otl] +25; C =0.4 (ehnl) 2) Preparation of (-)-(4-((4-nitrophenyl)hydroxymetyL)phenyl ,5-di tlio-( 3 -D-Xylop~yranosid~e Example 1’7 I2
I
0 The fi ttrate F I) is evalporalted in vanuo ard the residLie is taken01 Lip with ethyil acetaite containiup less thanm 100 ppmn of wat cr. Af ter crystallizat Lon 3.9 g o f c r y stalIs (C u re o bLa i ne d c 4.6 C 0.4 5 (ineth an o).
Th e c r ys tal (I 9 sr r ec r ys taI Iized f rom 1 30 m o ethlIz aceLtte contaiining Less thain 100) ppm o f wat cr. This gives 1,.44 g of crystals ((2)I 10 C 0.,3 5 metLha nol) Th E c r ystLalIs C r ersa~zdfo ml of ethyl aicetate contain in, less~ than 100 ppm o f wa tfr. Th is gi1ves 0, 96 p, of c r y stalIs o t hie is omer melIt ing f rurn 15 7 to 16 3 2′( 0 1 15; C 0.
(m et h an o)) PR-EPARATION XXI PreparlLion of 2-c varophunyl 4-munrcoptophunyl riethanone Following te procedlurte de.scribed in Prepara tion I1 arid starting froml g (0.059 mo 1) of 2-cyn no pheny’ 4-hydroxyphenyl methinonQ Anid i. 5 (0.068 ;a ol) )f di ie thy 1. hiocaorbamoy I chloride, 16.5 fzg (yield: 9. o of 2-c yanobenny~ i hnldime(thiyl tlhiocirbamai~te melting at 138″‘C are ol.ta mnd.
Following 4he. procoure- descrihudl in Prepairotion IIT and starting froui 16 g (0.052 not of 0- 4 -(2-cyanoberizoyl )phenyt dlmutliyl thiocorbamiate, 10.9 g (yield; 68%) of’ S-4–(2-cynnobcnzoyl) Phunyl clixethyl thioCarbcunato mlc,.Ltig at I 12″C arc obtained.
Fol lowing. the procedure described in Preparation III2 and starting from 10.6 g (0.034 mol) of S-4-(2cyanobcrnzOyl)phenyi dimothylthiocarbamn9te, 9 g (yield: of 2-cytiniphionyl 4 mcrcaptopljenyl. nethanone me~ltitng at 102″ o~ re o bt trued.
fR.RPARATFON XXII ‘Preparation of 3-c yano p le iyl4 4-mc rca ptLophenyl N~Huothaone rcil low i the, prcodiirQ descvtbcd I1n PrepaWra t too Lffi~-~ -21 I and starting from 27 g (0.121 mol) of 3-cyanophenyl 4hydroxyphenyl methanone and 17.2 g (0.138 mol) of dimethylthiocarbamoyl chloride, 35 g (yield: 88%) of 0-4-(3-cyanobenzoyl)phenyl dimethylthiocarbamate melting at 160°C are obtained.
Following the procedure described in Preparation II and starting from 33 g (0.106 mol) of 0-4-(3-cyanobenzoyl)phenyl dimethyLthiocarbamate, 25 g (yield: 79%) of S-4-(3-cyanobenzoyl)phenyl dimethylthiocarbamate melting at 1500C are obtained.
Following the procedure described in Preparation III and starting from 22.6 g (0.073 mol) of S-4-(3cyanobenzoyl)phenyl dimethylthiocarbamate, 16.5 g (yield: 94.8%) of 3-cyanophenyl 4-mercaptophenyl methanone melting at 126°C are obtained.
Without implying a limitation, a number of compounds of the formula I according to the invention have been collated in Table I below and a number of their acetylated derivatives have been collated in Table II below.
The physical characteristics of the compounds according to the invention have been summarized in Tables I and II.
The antithrombotic activity of the products according to the invention was demonstrated by the following protocol for venous thrombosis: A venous stasis is produced under hypercoagulation according to the technique described by WESSLER et al. Applied Physiol. 1959, p. 943-946).
As in the technique described by J. HAUPMAN et al.
(Thrombosis and Haemostasis 43 1980, p. 118), the hypercoagulant used is a solution of activated factor X supplied by the company Flow Laboratories (71 Knat per 12.5 ml of physiological serum).
rll 22- The study is performed on unfasted male Wistar rats weighing 250 to 280 g (groups of 10 animals).
The test products are administered orally as a suspension in PEG 400. A thrombosis is induced 4 hours after this treatment and the thrombus formed is removed and weighed.
The results obtained at a dose of 12.5 mg/kg p.o.
(unless indicated otherwise) have been collated in Table III. The results obtained with the known products of the above-mentioned prior art have also been collated in this Table.
The venous antithrombotic activity of the products according to the invention is 2 to 16 times greater than that of the known products of the prior art.
The reaction mixture is heated at 50 0 C for two hours, with vigorous stirring. The mixture is then cooled to 0 0 C and a solution of 3.5 g (0.029 mol) of dimethylthioii C 1 3 11 1~11111~ ;;i 23 TABLE I HO R HO R
OH
Ex. A 8 R M.p. [o] 20 w/v)
D
1 S CO 4-NO0 183 60 a 2 0 C 12 4-NO2 166 21 b 3 S CHOH 4-NO 2 65 to 80 8 I 4 S CU 2 4-NO 2 16:3 10 b S CHOH H 160 to 190 11,5 b 6 8 CH0H 4-Cl 169 15.5 b 7 S CHOH 3-NO 2 60 to 88 20.3 b 8 0 CHOH 4-NO 2 108 to 118 7 b 9 0 CIHOH 4-CI 110 to 135 26 (0.18) b 0 CO 4-NO 2 196 51 (0.15) b 11 0 CO 4-Cl 214 56 (0.15) b 12 S CO 4-CN 164 53 (0.197) b 13 S C1OH 4-CN 70 to 85 2.8 (0.598) b 14 0 CH 2 4-Cl1 184 45 (0.154) b S CO 4-Cl1 160 50 (0.26) b 16 S CHOH 4-N0 2 141 25 b 17 S CHOH 4-NO0 2 157 to 163 15 b 18 S CO 3-CN 210 41.2 c 19 S CO 2-CN 195 59.5 b i h;- Notes: (1) (2) (3) (4) (a) (b) (c) residual solvent: residual solvent: lyophilized product mixture of eopimers solvent: DMSO solvent: Ci O8i solvent: T 2.3% of 112 0 2.5% of T2 0 2 c 24 TAB3LE 11 AcO A AcO ~AcO A–1 4 4 4 4S 4 4 t~ (b mixture of diestereotsomers s olIv en t: C I IC 1 solvent: C11 3
OH
j LUIYL O’%ULCLL mixture (8 :1 v/v) as the eluent. This finally gives 18.6 g of the isomer (yield: 70%) melting at 166- 1690C, D 2 +92; C 0. 5 (GHC1 3 and 3.9 g of the TABIE III PRODUCT 2 INHIIBITION Ex. 2 7 6 E x. 3 87 E x. 3a 63 Ex. 4 72’- Ex. 5 It4 E, 6 61 E, 7 68 Ex 8 E. 95 7 Ex. 10 6 Ex 116 E x 12 6 H*X, 13 81 Ex. 14 3 0) VX 15 56 Ex 16 72 (1) Ex, 17 66 (1 Ex. 18 31 Ex. 19 54 A 14 B No tQs; A: comparison product described in 8xample 1 of European Patent DOCUmnft A-0133103 1:comlparison producL describc1 in Rxamnple 97 Of E QropJoCan Pa toont Document fl-0051023 (1:at a (lose of 7.5 mg/kg p.o.,

Claims (6)

1. An osi do derivati ve wiich, ‘is sol cted fron thc.. group consisting of: i) the ciDpavlhoyusd. f ‘,ho fornuli: yo- OY in which: R represents a hydrogen atom, a halogen atom, a nitro group or a cyano group, A represents the sulfur atom or the oxygen atom, B represents a CH U1014l or CO group and 2’ Y represents the hydrogen atom or an acyl group; and (i epimers thereof when B is CHOH. 2, An oside derivative according to claim 1, wherein the acyl group Y contains from 2 to 5 carbon atoms and represents the group CH 3 CO in particular.

3. dithio-P 3 -D-xylopyranoside.

4. (4-(4–Cyanobenzoyl)phenyl)-l ,-dithio- ~-D-xylo- pyranoside. 4 dithio-4-D-xylopyranoside.

6. A therapeutic composition which contains, in association with a physiologically acceptable excipient, at least one oside derivative selected from the group consisting of the P-D-phenylthioxylosides of the formula I and epimers thereof according to claim1 1.

7. Use of a substance belonging to the group of the D-phenylthioxylosides of the formula I and epiniers there- of according to, claim 1 fcm-r tcvpr1Pno an antithronibotic drug to be used in therapy for the treat- ment of disorders of the venous circulation. of cthyl ;-Icevate. The filrat utnined Is wzisheci With 27 S. A metho1 for the prcpc-i rat ion of n fl-D–phenyl1thiaxyl- oaide of the forMIIu I az:cordi no Lo clamr 1I, wherain: CI i acomp)ound of the forniula: __B in which A, B and R are defined as above, is reacted with a th loxylose deriv’a tive selec ted from the group consisting of the ha IogenoacylLh ioxyl os ides and acyithioxylosides of the formulae: Yo Po A:oo ”Ok HAl (VIIla) VI I Ib) in which Hal represents a halogen atom, such as Cl or Br (the bromine atom being the preferred halogen atom here), and Y represents an acyl group, especially an aliphatic acyl group containing a total of 2 to carbon atoms and preferably the acetyl group, in an inert solvent, at a rate of 1 mol of II to about 1.11 to 1 .2 mol of thioxylose derivative, in the presence of an acid acceptor or a Lewis acid and (ii) if necessary a deacylnt-.on reaction is carried out at a temperature between room temperature (15-25’C) and the reflux temperature of the reaction medium., in a CI- C4lower alcohol (preferably methanol), in the presence of a metal alcoholate (preferably magnesium inethylate or 8odium methylate),

9. The method according to claim 8, wherein the com- pound of the formula 11 in which A is S, Th is used acicic aria neating is concinueaci 1:01 4’1 IUULZ L IL organic phase is separated f rom the insoluble resId ue by in stage is prcaparod aiccording the folllcwiiig .9 t p a) cond ensa tio n, in ai s tronp, balsiC MCediur of clinthyi- amino thiocar banoyl1 chlor id L o f t hL Formula: 3 C “N-C-Cl H C if 3 S (III) with a phenol of the formula: HO -0 l 1 IV in which R and B have the meanings indicated above, to give a compound of the formula: H3 C 3 S (V) ii in which R and B are defined as above, b) rearrangement of the resulting compound of the formula V, by heating, to give a compound of the f ormula: H 3 C V H C ‘1 //(VE 3 0 in which R and B are defined as iodicated above and 111 -u uLC-U L.LLUU WULL-l till U LUIl -LyUP~IIiiJ-L;UU Lu 4 g (quantitative yield) of the expected product melting LI -1 4’ C L re-citien t of t hoc reu u A t lg c onpouind Of the formula VI with a metal alcoholate, preferably sodium or muagn es ium me tha n olIa te, in aiL C I- C 4 lower alcohol, p-)ref era bl1y noethoanolI, Ito g ive a t h iophenolI o f t hec f or mula,1 KS- _0B in which R and B are defined as indicated above. V I I o ~Ai 9 9 9 9 4, 4,9 4, 99 4, 4,4, 9 4, 9 4,9999w o I 4, II o I o gi 4, 99 99 9 41 #99 *1 4,~ t~ t1 I -D-.phenylthioxylosides of the formula I according t 15 claim 1, which is selected from the thiophenols the in which B and R are defi das indicated above, with the additional proviso hat R is different from H and 4-Cl when B is CO CH 2 DATE~D this 26th day of Ap~ril! 1988. FOURNIER INNOVATION ET SYNERGIE By their Patent Attorneys C. CVk-UGI’tJ C0. ‘I .1

AU15219/88A
1987-05-04
1988-04-27
Novel beta-d-phenyl-thioxylosides, their method of preparation and their use as therapeutics

Ceased

AU602210B2
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

FR8706237

1987-05-04

FR8706237A

FR2614893B1
(en)

1987-05-04
1987-05-04

NOVEL B-D-PHENYL-THIOXYLOSIDES, THEIR PREPARATION PROCESS AND THEIR APPLICATION IN THERAPEUTICS

Publications (2)

Publication Number
Publication Date

AU1521988A

AU1521988A
(en)

1988-11-10

AU602210B2
true

AU602210B2
(en)

1990-10-04

Family
ID=9350723
Family Applications (1)

Application Number
Title
Priority Date
Filing Date

AU15219/88A
Ceased

AU602210B2
(en)

1987-05-04
1988-04-27
Novel beta-d-phenyl-thioxylosides, their method of preparation and their use as therapeutics

Country Status (29)

Country
Link

US
(2)

US4877808A
(en)

EP
(1)

EP0290321B1
(en)

JP
(1)

JPH07103144B2
(en)

KR
(1)

KR960015109B1
(en)

CN
(1)

CN1020614C
(en)

AT
(1)

ATE68000T1
(en)

AU
(1)

AU602210B2
(en)

CA
(1)

CA1323373C
(en)

CZ
(1)

CZ278365B6
(en)

DD
(1)

DD269852A5
(en)

DE
(1)

DE3865230D1
(en)

DK
(1)

DK169873B1
(en)

ES
(1)

ES2026669T3
(en)

FI
(1)

FI87655C
(en)

FR
(1)

FR2614893B1
(en)

GR
(1)

GR3003415T3
(en)

HU
(1)

HU203362B
(en)

IE
(1)

IE61386B1
(en)

IL
(1)

IL86133A
(en)

MA
(1)

MA21260A1
(en)

NO
(1)

NO167035C
(en)

NZ
(1)

NZ224447A
(en)

OA
(1)

OA08840A
(en)

PT
(1)

PT87382B
(en)

SK
(1)

SK278297B6
(en)

SU
(1)

SU1567124A3
(en)

TN
(1)

TNSN88041A1
(en)

YU
(1)

YU46711B
(en)

ZA
(1)

ZA883031B
(en)

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU632411B2
(en)

1990-04-02
1992-12-24
Fournier Industrie Et Sante
Novel sulfonylphenyl-beta-d-thioxylosides, their method of preparation and their use in therapeutics

Families Citing this family (19)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US5246961A
(en)

1988-10-18
1993-09-21
Fournier Industrie Et Sante
β-d-phenylthioxylosides, and their use as therapeutic agents

IE63544B1
(en)

1988-10-18
1995-05-17
Fournier Ind & Sante
Novel Beta-d-phenylthioxylosides their method of preparation and their use in therapy

FR2648819B1
(en)

1989-06-21
1994-11-25
Fournier Innovation Synergie

NOVEL (BETA) -D-PHENYL-THIOXYLOSIDES, THEIR PREPARATION PROCESS AND THEIR USE IN THERAPEUTICS

FR2652353B1
(en)

1989-09-22
1994-02-11
Fournier Industrie Sante

NOVEL BENZOPYRAN-2-ONE-BETA-D-THIOXYLOSIDES, THEIR PREPARATION PROCESS AND THEIR USE IN THERAPEUTICS.

FR2659659B1
(en)

1990-03-16
1995-03-10
Fournier Ind & Sante

NOVEL BENZOPYRAN-4-ONE-BETA-D-THIOXYLOSIDES, THEIR PREPARATION PROCESS AND THEIR USE IN THERAPEUTICS.

CA2024476C
(en)

1989-09-22
1999-10-12
Soth Samreth
Benzopyranone-.beta.-d-thioxylosides their method of preparation and their use in therapy

FR2688221B1
(en)

1992-03-09
1994-05-20
Fournier Industrie Sante

ESTRATRIENOL-BETA-D-THIOXYLOSIDES, THEIR PREPARATION PROCESS AND THEIR USE IN THERAPEUTICS.

WO1994020116A1
(en)

1993-03-10
1994-09-15
University Of Alabama Research Foundation
Artificial primers for glycogen synthesis

HU9601756A3
(en)

1996-06-25
1999-05-28
Richter Gedeon Vegyeszet
New anticoagulant glycosides and pharmaceutical compositions containing them

HU9603341A3
(en)

1996-12-04
1999-05-28
Richter Gedeon Vegyeszet
Glucosides as blood-clotting-inhibitors and pharmaceutical compositions containing them

AU746680B2
(en)

1998-06-24
2002-05-02
Fournier Industrie Et Sante
Novel compounds derived from alpha-d-xylose, preparation method and therapeutic use

US6291433B1
(en)

1999-06-11
2001-09-18
Fournier Industrie Et Sante
Derivatives of α-D-Thioxyloside and their use against atheroma

WO2003064440A1
(en)

2002-01-31
2003-08-07
Morphochem Aktiengesellschaft für kombinatorische Chemie
Compounds that inhibit factor xa activity

DE10300049A1
(en)

2003-01-03
2004-07-15
Morphochem AG Aktiengesellschaft für kombinatorische Chemie

New compounds that inhibit factor VIIa

FR2860234B1
(en)

2003-09-25
2005-12-23
Fournier Lab Sa

NEW THIOXYLOSE DERIVATIVES 666

FR2883561B1
(en)

2005-03-25
2009-03-20
Fournier S A Sa Lab

NOVEL COMPOUNDS DERIVED FROM 5-THIOXYLOSE AND THEIR THERAPEUTIC USE

FR2903698B1
(en)

2006-07-13
2009-01-30
Fournier S A Sa Lab

NOVEL 5-THIOXYLOPYRANOSE DERIVATIVES.

FR2906248B1
(en)

2006-09-27
2008-12-26
Fournier S A Sa Lab

NEW 5-THIOXYLOPYRANOSE DERIVATIVES

FR2906247B1
(en)

2006-09-27
2008-12-26
Fournier S A Sa Lab

NEW 5-THIOXYLOPYRANOSE DERIVATIVES

Family Cites Families (7)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

US3243425A
(en)

1962-10-29
1966-03-29
Purdue Research Foundation
Novel sulfur-containing compounds

US3949002A
(en)

1970-11-13
1976-04-06
Imperial Chemical Industries Limited
Process for producing sulfone containing thiophenols

GB1585962A
(en)

1976-10-14
1981-03-11
Lilly Industries Ltd
Benzophenone derivatives

FR2492830A1
(en)

1980-10-29
1982-04-30
Sori Soc Rech Ind

NOVEL COMPOUNDS BELONGING TO THE BENZOYL- AND A-HYDROXYBENZYL-PHENYL-OSIDES FAMILY, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION

FR2549476B1
(en)

1983-07-20
1986-04-25
Rech Ind

BENZYL-PHENYL-OSIDES, PROCESS FOR PREPARATION AND THERAPEUTIC USE

US4515782A
(en)

1983-08-29
1985-05-07
American Cyanamid Company
Substituted phenyl-1-thio(poly-O-sulfo)-α(or β)-D-glucopyranosides

DE3725640A1
(en)

1987-08-03
1989-02-23
Bayer Ag

METHOD FOR PRODUCING THIOPHENOLS AND NEW THIOPHENOLS

1987

1987-05-04
FR
FR8706237A
patent/FR2614893B1/en
not_active
Expired

1988

1988-04-20
IL
IL86133A
patent/IL86133A/en
not_active
IP Right Cessation

1988-04-25
US
US07/185,422
patent/US4877808A/en
not_active
Expired – Fee Related

1988-04-26
CA
CA000565129A
patent/CA1323373C/en
not_active
Expired – Fee Related

1988-04-27
DE
DE8888401030T
patent/DE3865230D1/en
not_active
Expired – Fee Related

1988-04-27
ES
ES198888401030T
patent/ES2026669T3/en
not_active
Expired – Lifetime

1988-04-27
EP
EP88401030A
patent/EP0290321B1/en
not_active
Expired – Lifetime

1988-04-27
AT
AT88401030T
patent/ATE68000T1/en
not_active
IP Right Cessation

1988-04-27
JP
JP63107482A
patent/JPH07103144B2/en
not_active
Expired – Lifetime

1988-04-27
AU
AU15219/88A
patent/AU602210B2/en
not_active
Ceased

1988-04-28
ZA
ZA883031A
patent/ZA883031B/en
unknown

1988-05-02
NO
NO881921A
patent/NO167035C/en
unknown

1988-05-02
MA
MA21501A
patent/MA21260A1/en
unknown

1988-05-02
TN
TNTNSN88041A
patent/TNSN88041A1/en
unknown

1988-05-02
PT
PT87382A
patent/PT87382B/en
not_active
IP Right Cessation

1988-05-02
FI
FI882043A
patent/FI87655C/en
not_active
IP Right Cessation

1988-05-02
NZ
NZ224447A
patent/NZ224447A/en
unknown

1988-05-03
OA
OA59342A
patent/OA08840A/en
unknown

1988-05-03
HU
HU882258A
patent/HU203362B/en
not_active
IP Right Cessation

1988-05-03
SK
SK2979-88A
patent/SK278297B6/en
unknown

1988-05-03
IE
IE132488A
patent/IE61386B1/en
not_active
IP Right Cessation

1988-05-03
CZ
CS882979A
patent/CZ278365B6/en
unknown

1988-05-03
DK
DK239788A
patent/DK169873B1/en
not_active
IP Right Cessation

1988-05-03
SU
SU884355706A
patent/SU1567124A3/en
active

1988-05-03
CN
CN88102569A
patent/CN1020614C/en
not_active
Expired – Fee Related

1988-05-03
DD
DD88315327A
patent/DD269852A5/en
not_active
IP Right Cessation

1988-05-04
YU
YU86988A
patent/YU46711B/en
unknown

1988-05-04
KR
KR1019880005172A
patent/KR960015109B1/en
not_active
IP Right Cessation

1989

1989-06-27
US
US07/371,775
patent/US4996347A/en
not_active
Expired – Fee Related

1991

1991-12-20
GR
GR91402113T
patent/GR3003415T3/en
unknown

Cited By (1)

* Cited by examiner, † Cited by third party

Publication number
Priority date
Publication date
Assignee
Title

AU632411B2
(en)

1990-04-02
1992-12-24
Fournier Industrie Et Sante
Novel sulfonylphenyl-beta-d-thioxylosides, their method of preparation and their use in therapeutics

Also Published As

Publication number
Publication date

CN88102569A
(en)

1988-12-14

FR2614893B1
(en)

1989-12-22

EP0290321B1
(en)

1991-10-02

YU86988A
(en)

1989-10-31

PT87382A
(en)

1989-05-31

SK297988A3
(en)

1996-09-04

KR960015109B1
(en)

1996-10-28

NO881921L
(en)

1988-11-07

JPS63280092A
(en)

1988-11-17

CZ297988A3
(en)

1993-07-14

NO881921D0
(en)

1988-05-02

FI882043A0
(en)

1988-05-02

CZ278365B6
(en)

1993-12-15

NO167035C
(en)

1991-09-25

DK239788D0
(en)

1988-05-03

EP0290321A1
(en)

1988-11-09

US4996347A
(en)

1991-02-26

SU1567124A3
(en)

1990-05-23

ATE68000T1
(en)

1991-10-15

IL86133A0
(en)

1988-11-15

IE61386B1
(en)

1994-11-02

US4877808A
(en)

1989-10-31

NZ224447A
(en)

1990-09-26

ES2026669T3
(en)

1992-05-01

KR880013916A
(en)

1988-12-22

CA1323373C
(en)

1993-10-19

OA08840A
(en)

1989-03-31

SK278297B6
(en)

1996-09-04

CN1020614C
(en)

1993-05-12

IE881324L
(en)

1988-11-04

HUT46923A
(en)

1988-12-28

NO167035B
(en)

1991-06-17

FI882043A
(en)

1988-11-05

ZA883031B
(en)

1988-11-01

AU1521988A
(en)

1988-11-10

JPH07103144B2
(en)

1995-11-08

TNSN88041A1
(en)

1990-07-10

FR2614893A1
(en)

1988-11-10

PT87382B
(en)

1992-08-31

DE3865230D1
(en)

1991-11-07

FI87655C
(en)

1993-02-10

DK239788A
(en)

1988-11-05

HU203362B
(en)

1991-07-29

IL86133A
(en)

1992-05-25

YU46711B
(en)

1994-04-05

DK169873B1
(en)

1995-03-20

MA21260A1
(en)

1988-12-31

DD269852A5
(en)

1989-07-12

FI87655B
(en)

1992-10-30

GR3003415T3
(en)

1993-02-17

Contact information